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HUNGRY BONE SYNDROME IN THYROTOXICOSIS AS A CAUSE OF 
POSTOPERATIVE HYPOCALCEMIA FOLLOWING TOTAL THYROIDECTOMY- A 
PROSPECTIVE STUDY 
BACKGROUND 
Postoperative hypocalcemia, a well known complication of total thyroidectomy has a higher 
incidence in thyrotoxic patients than euthyroids. Though hypoparathyroidism is considered to be 
the important cause, other potential causes such as hungry bone syndrome (HBS) is not well 
established. Therefore we designed this prospective case control study to test the causal of 
hypothesis of hungry bone syndrome as a cause of postoperative hypocalcemia after total 
thyroidectomy among thyrotoxic patients. 
 
MATERIALS AND METHODS 
Forty clinically active hyperthyroid patients and 31 age and sex matched euthyoid patients were 
included in the study and control group respectively. Bone mineral density (BMD) at femur, 
lumbar vertebrae and forearm were measured initially at the time of diagnosis and six after total 
thyroidectomy in both groups. Baseline serum corrected calcium, phosphorus, magnesium, 
alkaline phosphatase and 25-OH VitaminD and serially thereafter in the postoperative period 
were measured in either group. The results were analysed with SPSS ver. 20 and p value <0.05 
was considered significant. 
 
RESULTS: The mean age of hyperthyroid patients (M: F= 19:21) and euthyroid controls (M: F 
= 8:23) were 36.48+/-9.84 and 33.9+/-9.012 respectively. The incidence of postoperative 
hypocalcemia was higher among hyperthyroid cases at 82.5% as compared to 22.5% amongst 
euthyroid controls (Odd’s ratio=16.16, p<0.001). The incidence of HBS was 32.5% among 
thyrotoxic cases (Male: Female= 7:6) and constituted 39.5% of the cause for hypocalcemia. 
Transient hypoparathyroidism at71.4% constituted the major cause of hypocalcemia among 
euthyroid controls. Baseline BMD at femur, spine and forearm ( the values of which were 
0.8512+/-0.1647 g/cm2, 0.9846+/-0.1676 g/cm2 and 0.643+/-0.1133 g/cm2) were significantly 
lower than euthyroid controls (which were 1.012+/-0128 g/cm2, 1.129+/- 0.115 g/cm2 and 
0.751+/- 0.108 g/cm2, p<0.001). There was significant negative correlation between baseline 
femoral and lumbar BMD and serum alkaline phosphatase. Post treatment BMD revealed 
significant percent increment of 8.27% and 7.58% at femur and lumbar spine respectively. 
CONCLUSION: Post-thyroidectomy hypocalcemia was higher in thyrotoxic patient and HBS 
contributed to 39.5% of the cause whereas transient hypoparathyroidism was the major 
determinant among euthyroid controls. Elevated serum alkaline phosphatase and low 
preoperative magnesium (especially in young females) were the predictive risk factors among 
thyrotoxic and euthyroid controls respectively. 
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INTRODUCTION 
 
Postoperative hypocalcaemia is a common complication following 
thyroidectomy with reported incidence varying from 1.6 to as high as 
83%1-7. Damage, devascularization or inadvertent removal of the 
parathyroid glands is the most important determinant, but other potential 
causes include “hungry bone syndrome” (HBS) due to postoperative 
reversal of thyrotoxic osteodystrophy8, reactive hypoparathyroidism due 
to relative hypercalcaemia in thyrotoxic patients9 and release of calcitonin 
during operative manipulation10. Hungry bone syndrome usually occurs 
as a complication after parathyroidectomy for hyperparathyroidism. But 
hungry bone syndrome occurring after thyroidectomy for thyrotoxicosis 
has not been established as the cause of hypocalcemia in prospective 
studies.  Therefore, we designed this prospective case control study to 
determine the contribution of hungry bone syndrome as a cause of post-
thyroidectomy hypocalcemia among thyrotoxic patients. We evaluated 
the longitudinal changes in bone mineral density and factors related to 
bone mineral ion homeostasis among thyrotoxic patients. We compared 
the same with age and sex matched euthyroid controls.  
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AIM OF THE STUDY 
Primary objective: 
To prospectively evaluate the incidence of hungry bone syndrome 
as a cause of post-thyroidectomy hypocalcemia among thyrotoxic 
patients. 
 
Secondary objective: 
• To evaluate the changes in the bone mineral density at all three 
sites, namely, femur, lumbar vertebrae and forearm before and after 
definitive surgical treatment 
• To serially study the factors related to bone mineral ion 
homeostasis namely Serum calcium, phosphorus, magnesium, 25- 
hydroxy Vitamin D, intact Parathormone & Alkaline phosphatase 
and predict at risk patients likely to develop post operative 
hypocalcemia. 
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REVIEW OF LITERATURE 
 
Thyroidectomy is the most common endocrine surgery performed 
worldwide. Theodor Kocher was awarded noble prize in 1909 for his 
pioneering work in thyroid surgery. He recognized the importance of 
anti- and aseptic handling, hemostasis, and precise operative technique 
which led to a reduction in mortality from high initial figures (50%) to 
less than 4.5%. Currently, the mortality rate of thyroidectomy approaches 
zero. However, morbidity remains a subject of concern as it leads to 
extended hospital stay. Postoperative hypocalcemia and vocal cord 
paralysis due to injury to the recurrent laryngeal nerve are the most 
common complications of total thyroidectomy. 
Postoperative hypocalcemia is of particular concern because it 
manifests late usually in the 3rd or 4th postoperative day. This in turn 
requires prolonged patient hospitalization or readmission. Hypocalcaemia 
may be transient or permanent (persistent for more than 6 months after 
surgery). The reported incidence of transient hypocalcemia varies from 
1.6 to 53.5%. Permanent hypoparathyroidism after total thyroidectomy is 
found in 1.5 to 4% of the patients. 
  The causes of hypocalcemia after Total thyroidectomy are 
multifactorial.  
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Damage, devascularization or inadvertent removal of the 
parathyroid glands are the major determinants of hypoparathyroidism. 
The presence of retrosternal extension, concomitant neck dissections, 
hyperthyroidism, thyroiditis, thyroid carcinoma, experience of the 
surgeon, prolonged operative time, and number of parathyroid glands left 
insitu also contribute to hypocalcemia.  
FACTORS INFLUENCING HYPOPARATHYROIDISM 
SURGICAL ANATOMY OF PARATHYROID: 
Sound knowledge of anatomy together with meticulous tissue 
handling and safe surgical techniques help to preserve the vascularisation 
of the parathyroids. 
Superior parathyroid develop from the dorsal aspect of fourth 
pharyngeal endodermal pouch and more constant in position. It is usually 
situated in the posterior aspect of the junction of upper and middle third 
of the lateral lobe of thyroid. It is dorsal to the recurrent laryngeal nerve. 
Inferior parathyroid develops from the endoderm of the third 
pharyngeal pouch along with thymus. Due to the embryonic descent 
along with thymus, it is more inconstant in position. It is located near the 
inferior pole of the thyroid lobe or in the thyrothymic ligament and 
ventral to the recurrent laryngeal nerve. 
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ARTERIAL SUPPLY OF PARATHYROIDS: 
The arterial blood supply to the parathyroid is single and terminal. 
Both the superior and inferior parathyroids receive its blood supply from 
glandular branches of inferior thyroid artery in 80% of the cases. They 
may also derive blood supply from the branches of superior thyroid 
artery, anastomotic branches between the two system or Neubaer artery, 
tracheoesophageal branches and arterial branches from the thyroid 
capsule. Capsular dissection with ligation of individual branches rather 
than ligation of the trunk of inferior thyroid artery preserves the blood 
supply to the parathyroids.  
VENOUS DRAINAGE OF PARATHYROIDS: 
Venous infarction of parathyroids may be relieved by superficial 
incision of its capsule. 
NUMBER OF PARATHYROIDS PRESERVED: 
All the four parathyroids should be identified and preserved. At 
least three parathyroids should be preserved to maintain calcium 
homeostasis. Some authors argue that single well vascularised 
parathyroid gland is sufficient to prevent permanent hypoparathyroidism. 
When the vascularity of the parathyroid  is compromised or inadvertently 
removed, it is harvested and cut into fragments of less than 1 cu.mm and 
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autotransplanted into ipsilateral sternomastoid. This practice decreases 
the risk of permanent hypoparathyroidism to less than 1% 56, 57.  
IDENTIFICATION OF THE RECURRENT LARYNGEAL 
NERVE: 
Extensive dissection required for the identification of the RLN may 
jeopardize the vascularity of the parathyroids. 
OTHER CAUSES OF POSTOPERATIVE HYPOCALCEMIA 
(a) HYPOMAGNESEMIA 
Divalent magnesium ion is an orthosteric agonist at Calcium 
sensing receptor (CaSR) and has membrane stabilization and other 
physiological properties similar to Calcium ions. Both magnesium 
depletion and excess alters calcium homeostasis. Hypomagnesemia 
produces symptoms of neuromuscular irritability with or without 
concomitant hypocalcemia 15. Hypomagnesemia causes functional 
hypoparathyroidism (i.e.) it decreases parathormone (PTH) secretion 17-19, 
30 and increases target organ resistance to PTH as well as peripheral 
degradation of parathormone  20,21. Magnesium deficiency is common in 
intensive care unit patients on parenteral nutrition, postoperative patients, 
chemotherapy, malnutrition etc22-27. Therefore, it is important to monitor 
serum magnesium in patients with persistent  hypocalcemic symptoms 
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despite calcium therapy28. Magnesium replacement corrects 
hypocalcemia and hypokalemia. 
(b) POSTOPERATIVE HEMODILUTION 
The stress of surgery produces several metabolic alterations in the 
body. Acute volume loss during surgery triggers the pressor receptors in 
the carotid artery and the aortic arch and stretch receptors in the wall of 
the left atrium and the juxtaglomerular apparatus of the kidneys. These 
afferent stimuli cause the release of antidiuretic hormone (ADH) and 
activate the rennin-angiotensin system causing the release of aldosterone. 
Other afferent neurogenic stimuli related to the surgical trauma such as 
pain also causes activation of the above mechanisms. The end result of 
these mechanisms is fluid retention. In addition to the hormonal 
responses to a volume loss, there is a marked shift of fluid across the 
capillary beds into the blood stream. These phenomenon decreases the 
concentration of red blood cells (as measured by hematocrit) and cause a 
dilution in the serum protein concentration. This factor of hemodilution is 
attributed to the transient fall in total serum calcium levels in 
postoperative period after any major surgery and calcium levels return to 
normal preoperative value within 24-48 hours of surgery. Ionized serum 
calcium levels remains unaffected in this phenomenon. 
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(c)  HYPOCALCEMIA IN GRAVES’ DISEASE 
 Michie et al showed that an important cause for hypocalcemia after 
thyroidectomy for thyrotoxicosis was a rapid reversal of an osteodytrophy 
that existed before surgery. Excessive bleeding from increased 
vascularity in thyrotoxicosis may obscure surgical field and lead to 
parathyroid injury. In addition, autoimmune fibrosis compromising 
parathyroid vascularization may lead to hypoparathyroidism. 
(d) EFFECT OF BLOOD TRANSFUSION: 
 Hypocalcemia may occur with rapid blood transfusion. The 
anticoagulants such as citrates present in the transfused blood may form 
complexes with calcium and lower total calcium levels. 
(e) PREOPERATIVE INGESTION OF DRUGS 
 Anti-convulsants, chlorpromazine, diazepam, oral contraceptives, 
steroids and mithramycin have been known to cause hypocalcemia.  
    (f) HYPERPHOSPHATEMIA  
 Hyperphosphatemia can lower serum calcium.  
Hyperphosphatemia may occur due to hypoparathyroidism after total 
thyroidectomy or calcitriol supplementation.  Hyperphosphatemia inhibits 
1-alpha-hydroxylase activity in the kidney and decreases the conversion 
of 25-OH vitamin D to active 1, 25-Dihydroxy vitamin D. This in turn 
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aggravates hypocalcemia (due to reduced calcium absorption from the 
intestine). 
EFFECT OF HYPERTHYROIDISM ON SKELETAL SYSTEM: 
Thyrotoxicosis is defined as the clinical syndrome of 
hypermetabolism and hyperactivity that results when the serum 
concentrations of free thyroxine (T4), free triiodothyronine (T3), or both, 
are high. Hyperthyroidism is a subset of thyrotoxicosis characterized by 
increased synthesis and secretion of thyroid hormones. 
The first systematic study of the clinical effects of thyrotoxicosis 
on the skeleton was published in 19721. The skeleton is a metabolically 
active tissue in which mineralized bone is continuously remodeled by the 
coordinated recruitment of osteoclasts and osteoblasts that respectively 
cause bone resorption and bone formation. These processes are regulated 
by autocrine, paracrine, and endocrine pathways. Steroid hormones, 
particularly glucocorticoids, estrogens, androgens, and vitamin D, are 
particularly important regulators of bone metabolism. 
 In thyrotoxicosis, the processes of bone resorption, matrix 
deposition, and mineralization are accelerated and the activation 
frequency is increased. Osteoclast and osteoblast activities are both 
increased (albeit disproportionately), and the duration of the remodeling 
cycle is reduced by approximately 50%. The uncoupling of osteoclast-
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osteoblast activation leads to an increase in the ratio of bone surface 
undergoing resorption to that undergoing formation. The net result is loss 
of bone, amounting to approximately 10% of mineralized bone per cycle 
in severe thyrotoxicosis. In keeping with increased activity of both 
osteoclasts and osteoblasts, serum and urinary biochemical markers of 
bone turnover are high in thyrotoxicosis. They include markers of both 
bone formation (serum alkaline phosphatase and osteocalcin) and bone 
resorption (urinary excretion of pyridinoline and deoxypyridinoline cross-
links and hydroxyproline). 
 In addition to its direct effects on osteoclast-osteoblast cell 
function, thyrotoxicosis results in a negative calcium balance. Urinary 
calcium excretion is increased. Intestinal calcium absorption is decreased, 
and therefore fecal calcium excretion is increased. The increase in bone 
resorption raises serum calcium concentrations, sometimes enough to 
cause hypercalcemia. Any increase in serum calcium concentration 
inhibits parathyroid hormone secretion, thus accounting, at least in part, 
for the increase in urinary calcium excretion. Another consequence of 
decreased parathyroid hormone secretion is reduced renal conversion of 
25-hydroxyvitamin D (calcidiol) to 1, 25 dihydroxyvitamin D (calcitriol). 
Reduced activation of vitamin D is exacerbated by increased metabolic 
clearance of vitamin D and its metabolites. Normal calcium homeostasis 
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and parathyroid hormone secretion are restored after treatment for 
thyrotoxicosis. 
HUNGRY BONE SYNDROME (HBS)  
HBS is characterized by rapid, profound and prolonged 
hypocalcemia associated with hypophosphatemia and hypomagnesemia, 
due to an excessive bone remineralization.  HBS is caused by the shift of 
calcium ion along with phosphorous and magnesium in to the hungry 
bones due to the sudden removal of stimulus for high bone turnover. The 
sudden removal of high circulating level of PTH following 
parathyroidectomy in hyperparathyroidism (and thyroidectomy in 
thyrotoxicosis) leads to sudden arrest of osteoclastic bone resorption in 
the phase of active bone turnover. This leads to enhanced bone 
remineralisation. 
CLINICAL MANIFESTATION OF HBS 
Hypocalcaemia causes neuromuscular irritability and manifests as 
acral and perioral parasthesia, positive Chvostek sign and Trousseau sign, 
carpopedal spam, laryngospasm, stridor, cardiac arrhythmia and 
congestive heart failure.  In severe cases seizures, coma and death.  
PREDISPOSING FACTORS FOR HBS 
a) Advanced age 47 
b) High preoperative serum calcium 
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c) Two-fold elevation of serum alkaline phosphatase47 
d) Preoperative low magnesium and albumin47, 48 
e) Skeletal involvement( thyrotoxic osteodystrophy) 48-51 
f) Vitamin D depletion48-51    
g) number of functional parathyroid left behind 
BIOCHEMICAL CHANGES IN HBS 
 
* Serum corrected serum calcium decreases to 8 mg/dl within 48-72 
hours but further fall occurs after the fourth post-operative day in 
patients with HBS 47 
* Fall of Serum phosphate levels postoperatively 
* Hypomagnesaemia  
* 2- fold elevation of serum alkaline phosphatase 
Sudden fall in intact parathormone to less than 1.7+/-0.4 pmol/l in 
PHPT. In contrast to PHPT, hypocalcemia of  HBS in thyrotoxicosis is 
characterized by appropriate increases in parathormone. 
MANAGEMENT OF HBS 
Aim of the treatment  is to  
• Short-term - replenish the circulating calcium deficit.  
• Long-term normalizing the bone turnover and remineralising 
skeleton. 
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TREATMENT OF HYPOCALCEMIA 
Treatment of Acute hypocalcemia -   
• 1 to 2 ampoules  of Calcium gluconate (90 mg of elemental 
calcium per 10 mL ampoule) diluted in 50 to 100 mL of 5% 
dextrose is infused over 10 minutes  
• Persistent hypercalcemia- infusion of calcium gluconate  at a rate 
of 0.5-2.0 mg/kg/hour to maintain s.corrected calcium in low 
normal range 
• Oral calcium supplementation is started simultaneously with 
vitamin D or its analogues (to aid calcium absorption from 
intestine)  
• Correction of serum magnesium deficits- i.v magnesium sulphate 
at 48 mEq/ 24 hrs or oral Magnesium oxide200mg TDS for 3 days. 
Adverse effects of intravenous calcium therapy 
• Cardiac arrhythmias – rapid infusion>200 mg/100 mL of elemental 
calcium  
• local extravasation into soft tissues (local irritation – Calcium 
chloride) 
• Calcium phosphate  crystal deposition- Ectopic calcification 
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TREATMENT OF CHRONIC HYPOCALCEMIA- PERMANENT 
HYPOPARATHYROIDISM 
• Serum calcium is maintained at low normal range 
o Oral doses of 1 to 3 grams of elemental calcium in 3 to 4 
divided doses- calcium carbonate (40% elemental calcium), 
calcium lactate (13%), calcium citrate (21%) and calcium 
gluconate (9%) 
• Urinary calcium<4mg/kg/24hr ( screen for nephrocalcinosis and 
hypercalciuria) 
o Thiazide diuretics may be used 
o Avoid furosemide 
• If hypoparathyroidism- Serum 25 (OH) vitamin D levels 
maintained >20 ng/mL – vitamin D2or D3 or vitamin D 
metabolites supplementation 
o Calcitriol 0.25 mcg BD to 0.5 mcg QID 
• Replacement with PTH for Hypoparathyroidism 
o Teriparatide- recombinant parathormone (1-34) 20mcg/day 
s.c 
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MATERIALS AND METHODS 
 
STUDY DESIGN  :  Prospective case control study 
PERIOD OF STUDY : November 2011 to February 2014 
PLACE OF STUDY : Department of Endocrine Surgery,  
     Madras Medical College &  
Rajiv Gandhi Government General  
Hospital, Chennai-600003. 
 
SUBJECTS:   
A total of 71 patients admitted in our department for surgery of 
benign thyroid diseases were included in the study and categorized 
selectively into two groups namely, study and control group.  Institutional 
ethical committee’s clearance and informed consent was obtained. 
INCLUSION CRITERIA FOR STUDY/ TEST GROUP: 
• 40 consecutive newly diagnosed clinically active hyperthyroid 
patients  were recruited into the study/ test group 
• Confirmed biochemically  with elevated free triiodothyronine FT3, 
free tetraiodothyronine FT4 and suppressed Thyroid stimulating 
hormone TSH  
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• Confirmed by Technitium99m thyroid scintigraphy with increased 
radiotracer uptake and non- visualization of salivary glands 
• Etiology of hyperthyroidism- 18 cases of Graves’ disease and 22 
cases of toxic multinodular goiter  
• Patients likely to have surgery as the definitive modality of 
treatment- 
o Large volume goiter 
o Compressive symptoms of trachea, recurrent laryngeal nerve 
etc 
o logistic reasons requiring immediate definitive treatment,  
o cytology suspicious for malignancy,  
o associated ophthalmopathy,  
o patients planning for pregnancy within 4-6 months 
o Failure or non-compliance to medical treatment- antithyroid 
drugs. 
Technetium scintigraphy of diffuse toxic goitre 
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Technetium scintigraphy – Multinodular goiter 
 
 
 
 
 
 
 
 
 
EXCLUSION CRITERIA FOR STUDY GROUP: 
• Patients with other causes of reduced BMD  
o long term steroids 
o immunosuppressive drugs 
o Chronic liver and kidney diseases 
o uncontrolled diabetes mellitus 
o smokers 
o alcoholics 
• Parathyroid diseases  
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• Patients on Oral calcium and Vitamin D supplements, Thiazide 
diuretics 
 
INCLUSION CRITERIA FOR CONTROL GROUP 
36 cases of Age and sex matched euthyroid patients with benign 
multinodular goiter   were included in the controls.  Age variation up to 2 
years was allowed. Patients were recruited at the same time as the test 
patients to avoid seasonal variation in 25 OH vitamin D levels.  However, 
four male patients and 1 female patient were lost in the follow up and 
excluded from the study. 
EXCLUSION CRITERIA 
• Reoperative surgery 
• Neck dissection 
• Malignancy of thyroid 
• Retrosternal extension 
On admission, all subjects were subjected to thorough history 
taking and physical examination. Complete blood count, renal function 
test, liver function test, electrocardiogram, Ski gram of the chest, neck 
and thoracic inlet were done for anesthetic fitness. Specific investigations 
such as thyroid profile, thyroid autoantibodies, high frequency ultrasound 
neck, FNAC thyroid, 99mTc thyroid scintigraphy for confirming diagnosis. 
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Baseline BMD was evaluated at all three sites namely, femur, 
lumbar vertebrae and forearm using DEXA at the time of diagnosis of 
hyperthyroidism in the test group as well as euthyroid controls and 6 
months after total thyroidectomy. 
They were also analysed serially at the baseline, second and third 
post operative day and 6 months after surgery for the following 
biochemical indices, 
1. Serum Corrected Calcium 
2. Serum Phosphorus 
3. Serum Magnesium 
4. Serum 25-Hydroxy Vitamin D 
5. Serum Parathormone 
6. Serum Alkaline phosphatase (SAP) 
 Hyperthyroid patients received antithyroid drug Tab.carbimazole 
10-60 mg/day in three divided doses and Tab.propranolol 40-160 mg/day 
in three divided doses and followed up with 4 to 6 weekly thyroid 
function test. On achieving clinical and biochemical euthyroids, surgery 
was done. Total thyroidectomy was the procedure of choice in either 
group or standardized technique was followed in all cases. 
TECHNIQUE OF TOTAL THYROIDECTOMY  
 Under General Anesthesia, patient supine with neck 
hyperextension & reverse  Trendelenburg’s position, skin crease collar 
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incision made. Subplatysmal flaps raised superiorly up to the upper 
border of thyroid cartilage and inferiorly up to the sterna notch. Deep 
cervical fascia opened midline. Sternohyoid retracted and sternothyroid 
divided as high as possible and thyroid gland exposed.  Capsular 
dissection was carried out in the avascular plane.   
Sternothyroid laryngeal triangle was defined to identify external 
branch of superior laryngeal nerve (EBSLN). It is bounded medially by 
inferior constrictor and cricothyroid, laterally by superior pole of thyroid 
and anteriorly by sternothyroid muscle.  
Superior Thyroid artery is ligated in continuity flushed with 
superior pole of thyroid away from EBSLN. Middle thyroid vein if 
present is ligated. Thyroid lobe is retracted medially. Recurrent laryngeal 
nerve (RLN) was identified in the trachea esophageal groove and 
laryngeal entry point noted on both sides.   
The branches of the inferior thyroid artery are ligated separately 
very close to the gland. Efforts were taken to identify and preserve all 
four parathyroid glands. Superior parathyroid were identified on the 
posterior aspect of thyroid lobe within 1 cm from the intersection of RLN 
and inferior thyroid artery (ITA) dorsal to the RLN. Inferior parathyroid 
lie ventral to the RLN. If the parathyroid inadvertently was  removed or 
vascularity seemed compromised, then autotransplantation was done in 
the homolateral sternocleidomastoid muscle. Closed suction drain was 
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placed as per surgeon’s choice. Wound closed in layers. Surgical 
specimen sent for histopathological examination. 
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DENSITOMETRY METHODS: 
 Bone mineral density was measured by Dual energy X- ray 
Absorptiometry using the machine Lunar iDXA encore 2007 
version11.30.062 GE Co., Madison, WI 53717-1915. Femoral BMD was 
measured at Femur neck, trochanteric and intertrochanteric region 
bilaterally. Lumbar BMD was measured in lumbar vertebrae L1 to L4. 
BMD forearm measured in long bones of forearm. The in- vivo precision 
for DPA were 1.7%, 1.6% and 1.8% at femoral, lumbar and forearm 
BMD. BMD was expressed in g/cm2 , T- score (units of standard 
deviation from young healthy adult reference population) and Z- score 
(units of standard deviation from an age-, sex-, height-, and weight-
adjusted mean). Bone involvement was analysed as per World Health 
Organisation criteria for osteoporosis. 
Normal: T-score at or above -1 SD 
Osteopenia: T-score between -1 & -2.5 SD 
Osteoporosis:  T-score at or below -2.5 SD    
LABORATORY METHODS 
Overnight fasting venous sample were collected from all patients at 
700 to 800 hrs in calcium free test tubes and analysed for the following 
parameters. Free Triiodothyronine (2.0 – 4.4 pg/ml), Free Thyroxine 
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(0.79 -2.2 ng/dl) and Thyroid stimulating hormone (0.3-5.5 mIU/ml) are 
performed using ultrasensitive CLIA i.e. Chemiluminescent 
immunometric assay. Serum calcium was analysed by Arsenazo III 
method using  Beckman Coulter pvt ltd in Synchron CX9. The coefficient 
of variation was 1.9% from a mean of 9.25 mg/dl. The corrected calcium 
(mg/dl) level was calculated by the formula (calcium concentration [mg/ 
dl] + 4-albumin [g/dl]) X0.8. Serum alkaline phosphatase (40-115 IU/L) 
was analysed by PNPP (p-nitrophenyl phosphate) and had a coefficient of 
variation of 5.8% from mean 107.0 IU. Serum phosphorus  (2.5 -4.5 
mg/dl) by Phosphomolybdate method using Beckman Coulter pvt ltd in 
Synchron CX9. Serum magnesium(1.7-3 mg/dl) was analysed by 
Calmagite method using Griner private ltd. in photometer 5010. Serum 
intact parathormone was measured by two site Chemiluminescent 
immunometric assay using Siemens pvt. Ltd with reference range ( 12 -
65pg/ml).Serum 25-OH vitamin D3 was measured  by Chemiluminescent 
immunometric assay using Siemens pvt. Ltd ADVIA centaur with 5.4% 
coefficient of variation from mean 24.9 ng/ml with reference range as 
Deficiency< 12, insufficiency12-30, sufficiency>30 and Toxic >100 
ng/ml. 
Hypocalcaemia was defined as  mild if serum corrected Ca2+ 7.8 to 
8.3 mg/dl (i.e)1.96 –2.09 mmol/L and Severe if corrected Ca2+  < 7.8 
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mg/dl (<1.95 mmol/L ); the normal range for Ca2+ was 8.4 to 10.2 mg/dl 
(2.10 to 2.55 mmol/L).  Mild hypomagnesemia was defined as serum 
Mg2+ <1.7 mg/dl and  severe hypomagnesemia if serum Mg2+< 1.4 mg/dl; 
normal range was 1.7 – 3.5 mg/dl 
Permanent hypoparathyroidism was defined by the requirement for 
oral calcium or vitamin D supplementation after 6 months from the time 
of thyroidectomy to maintain a eucalcemic state 11,12. 
Symptoms of “hypocalcemia” were defined as acral or perioral 
paresthesia, carpopedal spasm, seizures, laryngeal stridor, or cardiac 
arrhythmias. Patients had Trousseau and Chvostek signs recorded after 
surgery. Severe hypocalcemia was treated with infusion of calcium 
gluconate at 1.5-2 mg/kg/hr and simultaneously with oral calcium 
carbonate ( up to 3g/day elemental calcium) and calcitriol( up to 2 
mcg/d). IV magnesium sulphate 2g/d and oral magnesium oxide 200mg 
TDS for 3 days may be required in hypomagnesemic patients. These 
patients were followed more frequently. 
STATISTICAL ANALYSIS  
Data were expressed as mean+/- standard deviation. Statistical 
analysis was performed with IBM SPSS statistics version 20.0. by two 
tailed paired student t- test, two tailed unpaired student t- test, Chi – 
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square test and analysis of variance ANOVA where appropriate. P value 
<0.05 was considered significant. 
RESULTS 
PROSPECTIVE CASE CONTROL STUDY
case, 40, 56%
control, 31, 
44%
 
 
  A total of 71 patients were included in the series. Study group 
consisted of 40 clinically active hyperthyroid cases and control group 
consisted of 31 euthyroid patients.  Initially 36 patients were recruited 
in the control group but 34 men and I woman were  lost in the follow up 
and excluded from the study. 
AGE DISTRIBUTION: 
Most of the patients in either group were in the third and fourth 
decade of life with mean age of 36.48+/-9.84 and 33.9+/-9.012 in the 
study and control group respectively. Statistically there was no difference 
between the two groups with regard to age distribution (P= 0.261). 
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GENDER DISTRIBUTION: 
Of the 40 hyperthyroid patients, there were 19 men and 21 women 
and among euthyroid controls, there were 8 men and 23 women. P=0.063. 
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P=0.261 
P=0.063 
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CLINICAL PRESENTATION 
Swelling in the front of neck in the region of thyroid was the most 
common presentation. However weight loss despite increased appetite 
was the next common presentation in study group.  The mean weight 
among hyperthyroid was( 47.2+/-8.6Kg) significantly lower than 
euthyroid controls( 52.4+/-5.2 Kg).  
CLINICAL PRESENTATION
0 5 10 15 20 25 30 35 40
goitre
palpitation
tremor
wt loss
ophthalmopathy
compressive symptoms
voice change
sticky throat sensation
CASE CONTROL
 
 
Sticky throat sensation with compressive symptoms were the next 
common presentation among euthyroid controls. 
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Clinical and biochemical indices analysed between the two groups 
are given in the following Table.  
 
S.No PARAMETERS CASE CONTROL P value 
1. Age in years 36.48+/-9.84 33.9+/-9.01 0.261 
2. Male: Female 19:21 8:23 0.063 
3. Weight in kg 47.2+/-8.6 52.4+/-5.2 <0.05 
4. Duration of disease in 
months 
7.5+/-5.9 7.26+/-3.19 0.837 
5. Duration of antithyroid 
drugs  in months 
3.25+/-1.15 -  
6. FT3 pg/ml 16.66+/-7.23 2.14+/-0.98 0.001 
7. FT4ng/dl 5.22+/-2.38 1.12+/-0.78 0.022 
8. TSHmIU/ml 0.011+/-0.018 2.84+/-1.15 0.043 
9. Anti Thyroperoxidase 
antibody 
607.46+/-365.015 4.25+/-2.225 0.001 
10. Anti Thyroglobulin 
antibody 
266.5+/-400.4 3.54+/-11.25 0.013 
 
Thus, in the study group, free hormones were elevated and TSH 
suppressed. In addition the thyroid autoantibodies, namely 
Antithyroglobulin antibody and Anti-Thyroperoxidase antibody were 
elevated. 
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HISTOPATHOLOGY CASE CONTROL 
 
Hyperplastic 
goitre 
14 Nodular colloid 
goiter 
14 
Toxic nodular 
goitre 
18 colloid cystic goiter 4 
Hashimoto's 
thyroiditis 
8 Follicular adenoma 6 
  Adenomatous goiter 2 
  Lymphocytic 
thyroiditis 
5 
TOTAL 
 
 40  31 
 
MAJOR COMPLICATION CASE CONTROL 
Transient hypocalcemia 32 7 
Permanent Hypocalcemia 1 - 
Temporary recurrent laryngeal nerve palsy 3 1 
Permanent recurrent laryngeal nerve palsy 1 - 
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The biochemical indices related to bone mineral ion homeostasis 
which were measured serially are tabulated & compared between the 
study group and controls. 
PARAMETERS CASE CONTROL P VALUE 
 
PRETREATMENT 
 
 
S.CORRECTED 
CALCIUM mg/dl 
9.13+/-0.66 9.45+/-0.73 0.055 NS 
 
S.PHOSPHOROUS mg/dl 4.12+/-0.76 3.99+/-0.85 0.054 
 
NS 
S.MAGNESIUM mg/dl 1.78+/-0.67 2.18+/-0.45 0.004 
 
S 
S. INTACT 
PARATHORMONE 
pg/ml 
50.56+/-35.61 42.66+/-16.73 0.218 NS 
S.ALKALINE 
PHOSPHATASE IU/L 
143.18+/-72.0 71.97+/-23.07 <0.001 S 
S.25OH VITAMIND 
ng/ml 
24.27+/-10.61 26.12+/-14.63 0.555 NS 
 
 
From the above table, we observed that serum magnesium was 
significantly in the low normal range among hyperthyroid patients 
compared to euthyroid controls in the pretreatment phase. Serum alkaline 
phosphatase was two-fold higher than euthyroid controls. 
The preoperative corrected serum calcium levels were in the 
normocalcemic range  with mean value 9.13+/-0.66 among thyrotoxic 
patient in contrast to hypercalcemia reported in western literature. We 
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also observed that the 25-OH vitamin D were in the insufficient range in 
both groups and  preoperative parathormone was high normal. The 
prevalence of  hypovitaminosis D in our population leading to secondary 
hyperparathyroidism could be the probable reason. 
 
PARAMETERS CASE CONTROL P VALUE 
 
POSTOPERATIVE PHASE 
 
S.CORRECTED 
CALCIUM mg/dl 
7.715+/-0.81 8.961+/-0.771 <0.001 S 
 
S.PHOSPHOROUS 
mg/dl 
4.16+/-1.20 4.23+/-0.76 0.792 NS 
 
S.MAGNESIUM 
mg/dl 
1.95+/-0.79 1.95+/-0.46 0.974 NS 
 
S. INTACT 
PARATHORMONE 
pg/ml 
29.67+/-21.97 18.89+/-12.73 0.012 S 
S.ALKALINE 
PHOSPHATASE 
IU/L 
120+/-51.99 65.68+/-20.34 <0.001 S 
 
POSTOPERATIVE PHASE 
  Marked hypocalcemia was observed in the study group with a 
mean of 7.715 +/- 0.81 mg/dl in the postoperative phase. The magnitude 
of severity of hypocalcemia was also high as compared to the controls. 
However, intact parathormone was in the normal range among 
hyperthyroid cases. But it was significantly reduced in the control group. 
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Serum alkaline phosphatase showed two fold rise in the postoperative 
period in the study group. 
FOLLOW UP 
 
PARAMETER 
 
CASE CONTROL P VALUE 
S.CORRECTED CALCIUM 
mg/dl 
8.88+/-0.69 8.58+/-1.72 0.927 NS 
 
S.PHOSPHOROUS mg/dl 3.80+/-0.67 3.94+/-0.73 0.44 NS 
 
S.MAGNESIUM mg/dl 2.21+/-0.34 2.26+/-0.32 0.533 NS 
 
S.INTACT 
PARATHORMONE pg/ml 
60.17+/-38.44 40.28+/-16.07 0.006 S 
S.ALKALINE 
PHOSPHATASE IU/L 
102.52+/-8.26 67.78+/-13.68 <0.001 S 
  
Serum calcium returned to normocalcemic range 6 months after 
surgery in the hyperthyroid group.  Intact parathormone climbed up to 
high normal range among throtoxic cases. Though there was a fall in 
serum alkaline phosphatase in the follow up, it still remained higher than 
euthyroid controls.  
COMPARISON WITHIN THE GROUP  
WITHIN THE STUDY GROUP 
We observed a very significant fall in the level of serum calcium in 
the postoperative period. Though there was a drop in the parathormone 
postoperatively it was still in the normal range. Serum alkaline 
phosphatase remained two – fold higher than normal range. 
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ST UDY GROUP PREOPERATIVE VS POSTOPERATIVE 
 
PARAMETER PREOPERATIVE POSTOPERATIVE P VALUE 
S.CORRECTED 
CALCIUM mg/dl 
9.13+/-0.66 7.715+/-0.81 <0.001 
 
S.PHOSPHOROUS 
mg/dl 
4.12+/-0.76 4.16+/-1.20 0.829 
S.MAGNESIUM 
mg/dl 
1.78+/-0.67 1.935+/-0.79 0.319 
S. INTACT 
PARATHORMONE 
pg/ml 
50.56+/-35.61 29.67+/-21.97 0.005 
S.ALKALINE 
PHOSPHATASE IU/L 
143.18+/-72.0 120+/-51.99 0.011 
 
STUDY GROUP- POSTOPERATIVE VS FOLLOW UP 
 
PARAMETER POSTOPERATIVE FOLLOW UP P 
VALUE 
S.CORRECTED 
CALCIUM mg/dl 
7.715+/-0.81 8.88+/-0.69 
 
<0.001 
S.PHOSPHOROUS 
mg/dl 
4.16+/-1.20 3.80+/-0.67 0.035 
S.MAGNESIUM mg/dl 
 
1.935+/-0.79 2.21+/-0.31 0.020 
S. INTACT 
PARATHORMONE 
pg/ml 
29.67+/-21.97 60.17+/-38.44 <0.001 
S.ALKALINE 
PHOSPHATASE IU/L 
120+/-51.99 102.52+/-8.26 0.041 
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Serum calcium  restored to normocalcemic range with concomitant 
increase in serum parathormone. Serum magnesium and phosphorus also 
returned to normal range.  Though serum alkaline phosphatase showed a 
significant drop, it still remained elevated especially in those with 
osteoporosis or osteopenia.  One  case of permanent hypoparathyroidism 
occurred in the study group. 
COMPARISON WITHIN THE CONTROL GROUP  
 
We documented a significant fall in the level of corrected serum 
calcium and magnesium  along with a rise in the level of phosphorus 
postoperatively in the euthyoid controls. Intact parathormone showed a 
significant drop to low normal values. 
PARAMETER PREOPERATIVE POSTOPERATIVE 
P 
VALUE 
 
S.CORRECTED 
CALCIUM mg/dl 
9.45+/-0.73 
 
8.961+/-0.771 0.005 
S.PHOSPHOROUS 
mg/dl 
3.99+/-0.85 4.23+/-0.76 0.08 
S.MAGNESIUM mg/dl 2.18+/-0.45 
 
1.95+/-0.46 0.039 
S. INTACT 
PARATHORMONE 
pg/ml 
42.66+/-16.73 18.89+/-12.73 <0.001 
S.ALKALINE 
PHOSPHATASE IU/L 
71.97+/-23.07 65.68+/-20.34 0.021 
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In the follow up surveillance, we documented  a significant 
increase in the intact parathormone with  normalization of calcium and 
phosphorus. Serum magnesium also improved significantly. All patients 
became asymptomatic.  
CONTROL GROUP - POSTOPERATIVE VS FOLLOW UP 
 
PARAMETER POSTOPERATIVE FOLLOW UP P VALUE 
 
S.CORRECTED CALCIUM 
mg/dl 
 
8.961+/-0.771 8.58+/-1.72 0.313 
S.PHOSPHOROUS mg/dl 
 
4.23+/-0.76 3.94+/-0.73 0.043 
S.MAGNESIUM mg/dl 
 
1.95+/-0.46 2.26+/-0.32 0.001 
S. INTACT 
PARATHORMONE pg/ml 
18.89+/-12.73 40.28+/-16.07 <0.001 
S.ALKALINE 
PHOSPHATASE IU/L 
65.68+/-20.34 67.78+/-13.68 0.903 
 
There was no significant change in the levels of serum alkaline 
phosphatase among the euthyroid controls.  
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EVALUATION OF BONE MINERAL DENSITY IN STUDY VS 
CONTROL 
0
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BMD IN STUDY GROUP 
DEXA SCAN PRETREATMENT POST-TREATMENT 
NORMAL 5 12.5% 21 52.5% 
OSTEOPENIA 17 42.5% 11 27.5% 
OSTEOPOROSIS 18 45% 8 20% 
TOTAL 40 100% 40 100% 
 
Pretreatment DEXA revealed bone involvement in 87.5% of the 
hyperthyroid cases initially at the time of diagnosis of hyperthyroidism. 
We documented osteopenia in 42.5% and osteoporosis in 45% of the 
P=0.001 
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hyperthyroid cases. Post-treatment DEXA scan taken 6 months after 
surgery showed significant improvement in the BMD (p<0.001) and 
normalized in 52.5% of the cases. 
0
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BMD IN CONTROL GROUP 
DEXA PRETREATMENT POST-TREATMENT 
NORMAL 20 64.51% 23 74.19% 
OSTEOPENIA 10 32.25% 8 25.80% 
OSTEOPOROSIS 1 3.22% 0 0 
TOTAL 31 100% 31 100% 
 
 
On the other hand, pretreatment DEXA was normal in majority of 
the euthyroid controls and not much change after surgery.  
P=0.230 
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Baseline Femoral, lumbar and forearm BMD were 0.8512+/-
0.1647 g/cm2, 0.9846+/-0.1676 g/cm2 and 0.643+/-0.1133 g/cm2 
respectively among hyperthyroid cases and were 1.012+/-0128 g/cm2, 
1.129+/- 0.115 g/cm2 and 0.751+/- 0.108 g/cm2 respectively among 
euthyroid controls. Thus, BMD at all three sites were significantly lower 
among hyperthyroid s than euthyroid controls (p value<0.001). 
After definitive surgical management, the bone mass improved 
predominantly in the femur and lumbar vertebrae (p value < 0.001) 
among hyperthyroid cases. Although the bone mineral density did 
increase at forearm, the mean increment was not statistically significant 
(p value = 0.081). 
 
BMD IN STUDY GROUP
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P<0.001 
P<0.001
P<0.081
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The percent increment in the bone mass was highest in lumbar 
vertebrae at 8.27%, followed by femur at 7.58% and least in the forearm 
(2.95%). 
BMD IN CONTROLS
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There was not significant change in the BMD of the controls before 
and after treatment. 
P=0.264 P=0.405
P=0.087
 
42
 
HUNGRY BONE SYNDROME IN STUDY GROUP
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PRE & POST TREATMENT TOTAL BODY BMD 
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PRE  TREATMENT LUMBAR VERTEBRAE BMD -OSTEOPOROSIS 
 
 
 
POST TREATMENT LUMBAR VERTEBRAE BMD –OSTEOPENIA 
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PRETREATMENT & POSTTREATMENT – FEMUR 
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FAT CONTENT AND BODY MASS INDEX 
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All hyperthyroid cases received antithyroid medications for a mean 
duration of  3.25+/-1.15 months and became clinically & biochemically 
euthyroid preoperatively. Total thyroidectomy was performed in all 
subjects. Mean preoperative calcium was in the normocalcemic range in 
both groups. None of the patients had symptoms of hypocalcemia 
preoperatively.  Postoperatively biochemical hypocalcemia occurred in 
40 of 71 subjects i.e. 56.3% (Male: Female= 17:23) including 33 of 40 
hyperthyroid cases (Male: Female= 16:17) and 7 of 31 euthyroid controls 
(M:F=1:6). Thus, the incidence of postoperative hypocalcemia was higher 
among hyperthyroid cases at 82.5% as compared to 22.5% amongst 
euthyroid controls. This difference was statistically very significant with 
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Odd’s ratio=16.16, confidence interval 5.005 TO 52.19  and p<0.001.  
Nine of these patients were asymptomatic, 5 among hyperthyroid cases 
and 4 in euthyoid controls. 
 Postoperative hypocalcemia with concomitant hypomagnesemia 
and fall in serum phosphorus was documented in 13 thyrotoxic cases (13 
of 40 (i.e.) 32.5%, Male:Female= 7:6). All of these 13 hyperthyroid cases 
had profound, prolonged hypocalcemia manifesting 72 hours after 
surgery with cramps, carpopedal spasm and acral parasthesia requiring iv 
calcium infusion at 1.5-2mg/kg/hr. Oral calcium with vitamin D 
supplementation was also started simultaneously to high as 3g of calcium 
carbonate and 1 mcg of alfacalcidol. In addition i.v magnesium sulphate 
(10mmol/hr) infusion was given in 6 of these patients along with Oral 
magnesium supplementation. None of our patients had stridor nor cardiac 
arrhythmia. Three of these patients required calcium supplements for as 
long as 11 months.  However, postoperative hypocalcemia with 
concomitant fall in phosphorus and magnesium  was documented only in 
8 patients. 
The differences in the biochemical indices and BMD between 
those hyperthyroid hypocalcemic patients who developed Hungry bone 
syndrome and those who did not develop HBS are given in the table. 
 
HBS VS NON HBS HYPOCALCEMIC THYROTOXIC PATIENTS 
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 HBS VS NON 
HBS 
N Mean Std. 
Deviation 
P value 
PREOP SERUM 
CALCIUM 
HBS 13 9.2154 .63750 0.638 
NON-HBS 20 9.3200 .60489 
POSTOP SERUM 
CALCIUM 
HBS 13 7.6077 .73650 0.425 
NON-HBS 20 7.4050 .68324 
FOLLOW UP SERUM 
CALCIUM 
HBS 13 9.0769 .66728 0.150 
NON-HBS 20 8.6900 .77589 
PREOP SERUM 
PHOSPHORUS 
HBS 13 4.2308 .89479 0.79 
NON-HBS 20 4.1570 .70392 
POSTOP SERUM 
PHOSPHORUS 
HBS 13 3.2854 1.04161 0.001 
NON-HBS 20 4.7150 1.10752 
FOLLOW UP 
PHOSPHORUS 
HBS 13 3.6769 .63921 0.151 
NON-HBS 20 4.0045 .61540 
PREOP SERUM 
MAGNESIUM 
HBS 13 1.5762 .63117 0.060 
NON-HBS 20 2.0205 .64288 
POSTOP SERUM 
MAGNESIUM 
HBS 13 1.4646 1.05822 0.009 
NON-HBS 20 2.1980 .42276 
FOLLOW UP SERUM 
MAGNESIUM 
HBS 13 2.0431 .29775 0.000 
NON-HBS 20 2.4050 .22118 
PREOP INTACT 
PARATHORMONE 
HBS 13 55.0846 48.70439 0.372 
NON-HBS 20 43.0400 27.77997 
POSTOP INTACT 
PARATHORMONE 
HBS 13 35.0769 26.74983 0.168 
NON-HBS 20 23.4400 20.55014 
FOLLOW UP  INTACT 
PARATHORMONE 
HBS 13 72.1692 54.86973 0.246 
NON-HBS 20 54.8900 29.11447 
PREOP SERUM 
ALKALINE 
PHOSPHATASE 
HBS 13 158.6154 66.54264 0.469 
NON-HBS 20 138.6000 82.29881 
POSTOP SERUM 
ALKALINE 
PHOSPHATASE 
HBS 13 139.6923 42.64658 0.150 
NON-HBS 20 110.8500 61.26068 
FOLLOWUP SERUM 
ALKALINE 
PHOSPHATASE 
HBS 13 108.0000 53.70289 0.699 
NON-HBS 20 100.3500 55.97394 
SERUM 25 
HYDROXYVITAMIN D 
HBS 13 23.5577 12.57019 0.625 
NON-HBS 20 25.4840 9.78697 
 
 HBS VS NON 
HBS 
N Mean Std. 
Deviation 
Std. Error 
Mean 
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 HBS VS NON 
HBS 
N Mean Std. 
Deviation 
Std. Error 
Mean 
 
AGE OF THE 
PATIENT 
HBS 13 39.92 11.332 3.143 0.055 
NON-HBS 20 33.20 8.056 1.801 
GENDER HBS 13 1.46 .519 .144 0.632 
NON-HBS 20 1.55 .510 .114 
PREOP BMD 
FEMUR 
HBS 13 .77715 .138878 .038518 0.073 
NON-HBS 20 .88110 .168203 .037611 
POSTOP BMD 
FEMUR 
HBS 13 .84785 .141884 .039352 0.075 
NON-HBS 20 .95190 .168256 .037623 
PREOP BMD 
LUMBAR 
HBS 13 .87523 .137741 .038203 0.007 
NON-HBS 20 1.02445 .149185 .033359 
POSTOP BMD 
LUMBAR 
HBS 13 .97208 .156032 .043275 0.039 
NON-HBS 20 1.09635 .165721 .037056 
PREOP BMD 
FOREARM 
HBS 13 .64469 .115370 .031998 0.874 
NON-HBS 20 .63800 .118045 .026396 
POSTOP BMD 
FOREARM 
HBS 13 .63769 .087439 .024251 0.523 
NON-HBS 20 .66175 .114147 .025524 
PREOP FEMUR T 
SCORE 
HBS 13 -
2.23846
.901423 .250010 0.047 
NON-HBS 20 -
1.44500 
1.173154 .262325 
POSTOP FEMUR 
T SCORE 
HBS 13 -
1.53077 
.786749 .218205 0.045 
NON-HBS 20 -.61000 1.454901 .325326 
PREOP LUMBAR 
T SCORE 
HBS 13 -2.7538 1.21011 .33562 0.015 
NON-HBS 20 -1.6600 1.18117 .26412 
POSTOP 
LUMBAR T 
SCORE 
HBS 13 -1.9769 1.38633 .38450 0.041 
NON-HBS 20 -.9650 1.29301 .28913 
PREOP FEMUR Z 
SCORE 
HBS 13 -1.2385 1.11096 .30812 0.227 
NON-HBS 20 -.7150 1.24024 .27733 
POSTOP FEMUR 
Z SCORE 
HBS 13 -.7846 1.06759 .29610 0.132 
NON-HBS 20 -.1800 1.11572 .24948 
PREOP LUMBAR 
Z SCORE 
HBS 13 -
1.86923 
1.095738 .303903 0.010 
NON-HBS 20 -.79000 1.111613 .248564 
POSTOP 
LUMBAR Z 
SCORE 
HBS 13 -1.2769 1.22757 .34047 0.033 
NON-HBS 20 -.3650 1.09317 .24444 
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 The mean postoperative serum phosphorus and magnesium was 
significantly lower in the HBS subgroup as compared to non-HBS 
subgroup. Further, BMD was significantly lower at femur and lumbar 
vertebrae among those who developed hungry bone syndrome. In 
addition, postoperative PTH was normal or high normal in 10 of 13 
patients with HBS. Therefore hypoparathyroidism is unlikely to be the 
cause of hypocalcemia among HBS subgroup. 
 
 
 HBS HYPOCALCEMIA 
 cases cases Control 
Normal PTH 7 21 2(28.57%) 
Low PTH 3 6 5(71.4%) 
High PTH 3 4 - 
Total 13 33 7 
 
On the other hand, among euthyroid controls, transient 
hypoparathyroidism occurred in 5 of 7 patients with hypocalcemia 
(71.4%) and was the major determinant of postoperative hypocalcemia. 2 
patients had severe hypocalcemia requiring i.v calcium gluconate  and 
oral supplementation. Hypocalcemia and hypomagnesemia were 
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observed in 3 of these patients requiring oral calcium and magnesium 
supplementation. In another three patients, in the absence of biochemical 
hypocalcemia, symptoms of neuromuscular irritability occurred and were 
found to have hypomagnesemia. Mean preoperative & postoperative 
S.Magnesium were 2.17+/-0.454 and 1.95+/-0.46 mg/dl respectively 
among controls. Thus, there was significant fall in serum magnesium 
level in the postoperative period (p0.039) among controls in our series.  
 
 
 
 Cases Control 
Mild hypocalcemia 11 5 
Moderate hypocalcemia 5 2 
Severe Hypocalcemia 15 - 
Mild hypomagnesemia 6 - 
Severe Hypomagnesemia 13 3 
Hypomagnesemic 
hypocalcemia 
9 3 
 
Interestingly, preoperative serum magnesium were found to be 
lower in patients with Hypomagnesemic hypocalcemia syndrome in both 
study and control group. 
Among hyperthyroid patients, the higher the T3 concentration 
during hyperthyroidism and longer the duration of hyperthyroidism, the 
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greater was the subsequent increase in lumbar and femoral BMD. 
However, this was not statistically significant.  Further, BMD did not 
have correlation with advancing age nor hypovitaminosis. There was 
strong correlation between BMD and serum alkaline phosphatase( 
p<0.05). 
Hypovitaminosis D was prevalent in either group. The mean serum 
25 OH Vitamin D was 24.27+/-10.61 ng/ml among hyperthyroid vs. 
26.12+/-14.63 ng/ml  among controls (p= 0.804).  
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DISCUSSION 
Postoperative hypocalcemia is a common complication after total 
thyroidectomy with a reported incidence varying from 1.6 to above 50% 
and the cause is multifactorial. Hypoparathyroidism, being the  most 
widely accepted cause. Hungry bone syndrome characterized by rapid, 
profound and prolonged hypocalcemia associated with hypomagnesemia 
and hypophosphatemia is well established cause of hypocalcemia after 
parathyroidectomy for severe hyperparathyroidism. Though HBS is 
reported to occur post- thyroidectomy in thyrotoxic patients due to 
reversal of thyrotoxic osteodystrophy, its mechanism of cause is not well 
studied in prospective trials. 
 In our study, incidence of postoperative hypocalcemia was 56.38% 
(40/71), being significantly higher at 82.5% among hyperthyroid 
/thyrotoxic cases as compared to 22.5% among euthyroid controls 
(p<0.001).  
Pretreatment DEXA scan revealed bone involvement ( thyrotoxic 
osteodystrophy) in 85% of thyrotoxic patients as osteopenia in 17 patients 
(42.5%) and osteoporosis in 19 patients(45%). Baseline BMD was 
reduced in all three sites at femur, tibia and forearm with simultaneous 
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elevation of serum alkaline phosphatase indicative of high turnover bone 
disease. 
Out of 40 thyrotoxic cases, biochemical hypocalcemia occurred in 
33 cases. Among these hypocalcemic thyrotoxic cases, 13 patients had 
prolonged hypocalcemia after fourth postoperative day with concomitant 
hypomagnesemia and fall in serum phosphorus. In all of these patients, 
pretreatment DEXA revealed thyrotoxic osteodystrophy and 2-3 fold 
elevation of serum alkaline phosphatase.  Amongst these 13 patients, 
postoperative intact Parathormone were normal in 7 cases(53.8%), high 
in  three case(23.07%) and low in three cases(23.07%).  Therefore, 
hypoparathyroidism cannot be held as a reason for postoperative 
hypocalcemia in these thyrotoxic cases. Furthermore, concomitant 2-3 
fold elevation of  serum alkaline phosphatase postoperatively is 
suggestive of  active bone remineralisation. All these factors are 
suggestive of shift of the calcium ions along with magnesium and 
phosphorus ions into the hungry bones.  Thus, hungry bone syndrome 
constitutes one of the most important cause of postoperative 
hypocalcemia after total thyroidectomy in these patients with 
thyrotoxicosis. The incidence of HBS in the study group was 32.5% 
(13/40) and constituited  39.5% of the cases of hypocalcemia in the 
thyrotoxic group. 
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CAUSE OF HYPOCALCEMIA IN THYROTOXIC CASES
40%
18%
12%
9%
9%
12%
HBS
Hypoparathyroidism
Hypomagnesemic
hypocalcemia
Reactive hypercalcemia
Preop Mg Deficiency
Elevated SAP
 
The occurrence of hungry bone syndrome has been questioned in 
the literature because these thyrotoxic patients are rendered euthyroid 
before treatment thereby reversing the osteodystrophy. But treatment with 
antithyroid drugs are required for more than 6 months for reversal of 
osteodystrophy. On the other hand, mean duration of preparation with 
antithyroid drugs in our series was only3.25+/-1.15 months. 
Posttreatment DEXA revealed osteodystrophy in many as 22.5% of these 
thyrotoxic patients with elevation of alkaline phosphatase , which was 
suggestive of ongoing bone remineralisation even 6 months after surgery. 
Mitchie et al.8 refutes calcitonin release during surgical manipulation as a 
cause of hypocalcemia. 
  Hypomagnesemic hypocalcemia occurred in 4 of the 20 non-HBS 
hypocalcemic patients in study group (12.12%). Six cases had 
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hypoparathyroidism (16.12%). Hypomagnesemic hypocalcemia 
syndrome occurred in 4 cases(12.12%). Reactive hypercalcemia due 
secondary hyperparathyroidism contributed to 9.09%(3 cases). Three of 
the thyrotoxic cases had preoperative magnesium deficiency with normal 
serum alkaline phosphatase (9.09%). In the remaining 4 cases, we 
documented elevation of alkaline phosphatase(12.12%). In our series, 
serum alkaline phosphatase had a strong correlation with both 
pretreatment bone mineral density & postoperative hypocalcemia in the 
study group (p<0.05).  
 The incidence of postoperative hypocalcemia in euthyroid controls 
was 22.58%. Hypoparathyroidism was the major determinant accounting 
5 of 7 cases(71.4%). However, hypomagnesemia occurred in 7 of the 
euthyroid controls all of whom were young females. Three of these 
patients had concurrent hypocalcemia and required magnesium 
supplementation for resolution of the persistent symptoms despite 
calcium and vitamin D supplementation. Three other patients had 
symptoms of neuromuscular irritability in the absence of biochemical 
hypocalcemia. One other patient was asymptomatic. Thus, 6 of 7 patients 
(85.7%) with hypomagnesemia were symptomatic. Hypomagnesemic 
hypocalcemic syndrome (3/7) accounted for 42.8%  as a cause of 
hypocalcemia among euthyroid controls.  
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Demeester-Mirkine et al.29 concluded that postthyroidectomy 
hypocalcemia was multifactorial, due to a combination of hemodilution, 
temporary parathyroid insufficiency, and in thyrotoxic patients “hungry 
bone syndrome.” 
Wison et al.6  and Szubin et al. 14 reported that hypomagnesemia 
may lead to post-thyroidectomy tetany especially in the presence of 
hypocalcemia.  
In our study, actively hyperthyroid patients had significant reduced 
bone mineral density at femur, lumbar vertebrae and forearm. After six 
months of definitive surgical management, there was recovery of loss of 
bone mass at all three sites, but predominantly in the femur and lumbar 
vertebrae. 
 The first case of thyrotoxic osteodystrophy was reported in 1891 
by Von Recklinghausen31. Several radial and longitudinal studies of 
subjects with hyperthyroidism have demonstrated reduced bone density at 
various skeletal sites and reversal of bone loss with antithyroid therapy34, 
36-40. In a prospective study of 50 hyperthyroid patients previously 
conducted in our department, Udayakumar43 and co workers have 
demonstrated 4% increment in lumbar bone mass after one year of 
surgical management. But BMD was measured only at spine.    
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The present study demonstrated increase in bone mineral density 
by 7.58% at femur and 8.27% at lumbar vertebrae after treatment. 
Although there was increase in BMD in forearm by 2.95%, this 
improvement in BMD was not statistically significant (p = 0.081). A 
recently published study on 30 hyperthyroid patients of Indian origin, 
Dhanwal et al45., reported similar increase in bone mineral content by 
7.4% and 9.3% at hip and spine respectively, but there was deterioration 
at forearm by 6.7%. Lack of recovery or delayed recovery at forearm may 
be attributed to the predominance of cortical bone at this site. Cortical 
bone has lower activation frequency and lesser bone surface for 
remodeling when compared to trabecular bone. Lumbar vertebra is 
predominantly composed of trabecular bone. Femur is a composite of 
trabecular and cortical bone. This explains predominant bone 
remineralisation at these sites. 
 As per the literature41,42, patients with hypovitaminosis D & 
secondary hyperthyroidism showed significant bone loss at lumbar spine 
and hip. Mezquita et al11 & Collins et al39 reported that BMD at lumbar 
spine correlated with 25 OH vitamin D3 levels. However, in our present 
study, the mean Serum 25 OH vitamin D3 was in insufficient range in 
both study & control group and neither group showed significant change 
from baseline after definitive treatment. Serum 25 OH vitamin D3 did not 
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correlate with the bone mineral density and all the 3 control patients with 
Vitamin D deficiency had normal iDEXA scan. Studies44,45,46 on Indian 
population reports similar results. 
The mean serum calcium of 9.130+/-0.663 was in the 
normocalcemic range in contrary to hypercalcemia32, 33 in western 
population with hyperthyroidism. The widely prevalent vitamin D 
deficiency in our population may account for this normocalcemia46   and 
consequent secondary hyperparathyroidism. Neither advanced age nor 
hypovitaminosis D was a significant predictor of reduced bone density in 
our hyperthyroid patients. 
There were a few limitations in our study. We followed our 
patients for a shorter duration of 6 months only. Bone remineralisation at 
forearm   needs to be studied prospectively for a longer duration of more 
than a year. 
We conclude that Hungry bone syndrome is the major determinant 
of postoperative hypocalcemia in thyrotoxic patients. Reduced BMD in 
the femur and lumbar vertebrae with elevated alkaline phosphatase and 
intact parathormone are important predictive risk factors for postoperative 
hypocalcemia in thyrotoxic patients.  
Transient hypoparathyroidism is the major determinant of 
postoperative hypocalcemia in euthyoid controls. Magnesium deficiency, 
 
61
especially in young females are the predictive risk factors for 
postoperative hypocalcemia in euthyroid patients after total 
thyroidectomy. 
Hence, we recommend routine monitoring of calcium 
postoperatively in all patients, serum alkaline phosphatase in thyrotoxic 
patients and magnesium in euthyroid patients especially in young females 
and those with persistent hypocalcemic symptoms.  
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CONCLUSION 
 The incidence of post-thyroidectomy hypocalcemia was 
significantly higher in thyrotoxic patients than euthyroid controls. 
 The incidence of hungry bone syndrome was 32.5% and 
constituted the major determinant of postoperative hypocalcemia among 
thyrotoxic patients. 
Reduced BMD in the femur and lumbar vertebrae with elevated 
alkaline phosphatase and intact parathormone are important predictive 
risk factors for postoperative hypocalcemia in thyrotoxic patients.  
 
Transient hypoparathyroidism is the major determinant of 
postoperative hypocalcemia in euthyoid controls. Magnesium deficiency, 
especially in young females are the predictive risk factors for post-
thyroidectomy hypocalcemia in euthyroid patients. 
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 PATIENT INFORMATION SHEET 
 
Thyroid is an endocrine gland situated in the front of neck. Thyroid 
gland synthesizes  a chemical substance known as hormone – thyroxine , 
which is directly released  in to the blood stream and has its action on 
target organs. Some of the thyroid related diseases requires surgery. 
Thyroidectomy – complete removal thyroid gland. Thyrotoxicosis is a 
hypermetabolic state  due to excess circulating thyroid hormones and 
affects many organ system.  
It may affect the skeletal system and lead to loss of  bone mass, 
which may lead to bone pain, fractures etc. Definitive surgical 
management  reverse the bone loss. These changes in bone mineral 
density(BMD) can be measured by DEXA scanners. Further there are 
changes in the level of certain mineral ions such as calcium, phosphorus, 
magnesium etc. after thyroid surgery. This may cause symptoms of 
neuromuscular irritability. 
In this study we measure changes in the BMD and serum ca, 
phosphorus etc. before and after surgery. During this study, analysis of 
results, and publication of the study, the patients identity will not be 
revealed. The outcome of the study will be revealed to the patient on 
completion of the study ion request. 
 
 
Signature of the investigator   Signature of the patient 
 
Date 
Place 
  
 CONSENT FORM 
 
 
I Ms/Mr.________________________________M/O//F/O, B/O _______________________ 
Sex___________Hosp. No.________________ admitted in the Department  of Endocrine 
Surgery, Madras  Medical College  ,Chennai-3 on ____________  was explained by the 
doctor that I am provisionally diagnosed  to have  a thyrotoxicosis/ multinodular Goitre . 
 This condition requires thyroidectomy after work up and confirmatory diagnosis. 
I am willing  to be enrolled in the study undertaken to evaluate hungry bone syndrome in 
thyrotoxicosis as a cause of postoperative hypocalcemia with the aid of blood investigations, 
TFT, FNAC (invasive procedure) and DEXA (non invasive). The doctors have explained to 
me the nature and the purpose of the study. 
I have given my consent only after completely understanding the details that were explained 
to me.  
I am willing to be enrolled in this study without any  compulsion. 
I a am fully aware that I can withdraw from the trial at any time during the study and even 
then routine treatment as per the hospital protocol for  the thyroid disease   will be continued. 
I  am willing to go through DEXA scanner, a machine that produces two X-ray beams, each 
with different energy levels. One beam is high energy while the other is low energy. The 
amount of X-rays that pass through the bone is measured for each beam. This will vary 
depending on the thickness of the bone. Based on the difference between the two beams, the 
bone density can be measured. The radiation exposure from a DEXA scan is actually much 
less than that from a traditional chest X-ray. 
The precautions and adverse effects of DEXA used for analysing Bone mineral density were 
explained to me 
I have also given my consent for drawing blood sample for biochemical analysis during the 
study. 
I have given this consent to be enrolled in this study with my full consciousness 
 
 
 
 
 
Signature of the Investigator                                                          Signature of Patient 
 
Date : 11/11/2011 
Place: Chennai -3. 
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DATE 
 
NAME 
 
AGE 
 
SEX 
 
I.P.NUMBER 
 
DIAGNOSIS 
 
THYROID FUNCTION TEST 
 
FREE TRIIODOTHYRONINE 
 
FREE TETRAIODOTHYRONINE 
 
THYROID STIMULATING HORMONE 
 
ULTRASOUND OF THE THYROID 
 
Sl.no Parameters Study group Control Group 
Pre 
treatment 
Post 
op 
Follow 
up 
Pre 
treatment 
Post 
op 
Follow 
up 
1 Bone Mineral 
Density-DEXA 
      
2 S. Corrected 
Calcium 
      
3 S. Phosphorus        
4 S. Magnesium       
5 S. Parathormone       
6 S. Alkaline 
Phosphatase 
      
7 S. 25–OH Vitamin 
D 
      
 
 
SL.
NO NAME AGE SEX GROUP P Ca PO Ca F Ca P Ph PO Ph F Ph P Mg PO Mg F Mg P PTH PO PTH F PTH P SAP PO SAP F SAP P VITD Tross iv cal
PREOP 
BMD 
FEMOR
POSTOP 
BMD 
FEMUR
PREOP 
BMD 
LUMBAR
POSTOP 
BMD 
LUMBAR
PREOP BMD 
FOREARM
POSTOP BMD 
FOREARM
1 KASTHURI 55 F CASE 8.3 8.7 8.7 3.9 5.8 4.6 0.86 1.72 2.2 77.5 35 75 131 118 145 24 1 1 1.086 1.084 1.231 1.232 0.626 0.651
2 NATARAJAN 61 M CASE 8 8.3 9.2 2.2 1.7 2.7 0.96 0.8 1.72 54.5 36.1 80.4 87 173 112 55 2 0.618 0.648 0.724 0.79 0.544 0.561
3 HABIBULLAH 34 M CASE 8.6 8.6 9 4.2 4.6 2.8 1.13 2 1.9 35.5 45.6 44.9 103 122 64 34 2 1 1.126 1.119 1.28 1.394 0.663 0.739
4 MANOHARI 32 F CASE 9.2 7.2 9.3 4.4 7.1 5 0.7 2.4 2.4 21.4 5.49 9 79 63 77 23 3 3 0.934 1.144 0.838 1.088 0.605 0.601
5 PADMAVATHY 35 F CASE 9.3 8 9.1 4.6 4.5 4.4 0.91 1.04 1.8 49.4 0.4 42 137 113 86 22.1 2 2 1.104 1.106 1.112 1.152 0.654 0.658
6 DEVI 27 F CASE 9.3 8.6 10 4.6 2.6 4 0.9 1.04 1.64 81.3 68.9 177 166 141 73 10 2 1 0.853 0.941 1.101 1.276 0.884 0.843
7 VIJAYKUMAR 47 M CASE 8.9 8.3 9.4 4 2.4 3.1 0.88 0.97 1.8 26.1 47.3 33 137 179 66 35 2 1 0.84 0.924 0.926 1.124 0.736 0.743
8 VALLI 27 F CASE 9.4 8.2 9.2 4.5 3.4 3.5 0.85 2.3 2.4 43.3 16.3 37.3 40 41 41 14 2 2 1.13 1.161 1.036 1.046 0.717 0.666
9 LAKSHMIKANTHA 40 F CASE 8.8 8.9 9.3 3.8 3.7 2.5 1.5 3 2.3 79.3 29.9 28.8 74 77 61 22 1 1 0.904 0.944 1.201 1.242 0.648 0.689
10 MEGALAGANDHI 22 F CASE 10.5 8.2 9.1 3.7 3.9 3.4 0.95 1.4 2.7 71.1 25.8 67.3 70 65 55 34 1 1 0.903 1.034 1.146 1.256 0.652 0.626
11 RAVI 33 M CASE 9.1 8.6 9.4 4.6 3.9 3.5 0.8 0.83 1.7 20.7 29.7 23 140 118 86 21 2 2 0.87 0.923 0.96 1.121 0.83 0.887
12 ANJALI 25 F CASE 9.7 7.8 9.4 4.9 4.9 4 1.39 0.99 1.8 60.4 44.2 48 169 111 78 24 2 2 0.809 0.886 0.789 0.876 0.557 0.608
13 ELANJIUM 34 F CASE 10 7.2 8.8 4.3 3.2 3.8 1.9 1.2 2.2 37.5 68.5 68.5 135 119 115 11.29 3 2 0.867 0.951 0.986 1.046 0.786 0.687
14 VEERABATHIRAN 42 M CASE 8.7 5.9 8.1 2.6 3.6 5.5 2.6 1.33 2.4 64.6 0.01 16 82 61 74 21.3 3 3 1.233 1.241 1.425 1.529 1.038 1.032
15 INDIRA 30 F CASE 9.8 7.8 8 4.6 4.7 3.44 2.5 1.7 2.7 16.9 60 60 119 84 78 20.4 2 2 0.79 0.894 1.089 1.168 0.558 0.594
16 SUSHEELA 27 F CASE 9 7.9 8.4 3.6 4 3.4 1.3 1.5 1.9 27.3 18.9 28 103 76 77 14.24 2 1 0.823 0.926 0.907 1.046 0.679 0.688
17 NABEESA BEGAM 25 F CASE 8.2 9.4 9.4 2.4 3.2 3 1.5 1.5 1.2 72.8 24.1 62.6 73 73 74 6.91 1 1 0.889 0.882 1.119 1.134 0.776 0.685
18 ABIRAMI 35 F CASE 10.5 8.5 8.1 5.8 3.4 3.2 2.41 1.2 2.3 9.6 82.1 80 89 97 85 22.1 3 2 0.733 0.829 0.871 0.938 0.751 0.632
19 JAYANTHI 44 F CASE 9.4 6.6 7 5.3 6.2 4.2 1.7 1.53 2.5 61 8.6 72 81 81 50 33.6 3 3 0.841 0.973 1.039 1.065 0.635 0.82
20 ELUMALAI 50 M CASE 8.8 6.5 9.2 4.1 1.41 2.8 1.04 4.9 2.2 92.1 0.1 62 197 129 78 34 3 3 0.812 0.924 0.948 1.046 0.565 0.599
21 SELVAM 57 M CASE 9.3 7.2 8 4.5 3.8 4.6 1.8 1.2 2.7 5 19 193 148 176 248 10 2 1 0.691 0.827 0.806 0.907 0.608 0.603
22 DURGADEVI 26 F CASE 9.2 7.5 8.2 3.8 5.5 4.4 2.2 2.2 2.4 58.7 16.6 121.6 137 117 144 18 3 3 0.86 0.991 1.065 1.111 0.62 0.615
23 ELUMALAI.B  II 40 M CASE 9.4 7 9.8 5.2 4.2 4.6 2.5 2.2 2.2 5.7 41 83.6 140 212 196 23.9 1 1 0.732 0.765 0.798 0.853 0.58 0.605
24 VALLI II 28 F CASE 9.4 7 8.1 3.7 4.8 4.25 2.4 2.4 2.5 11.9 0.1 61.9 84 116 100 11.8 3 3 0.872 0.909 1.058 1.131 0.608 0.614
25 RADHA/MUNIYAMMAL 48 F CASE 9 8 9.3 5.1 4.8 4.2 2.4 2.9 2.8 35.1 16 42.4 87 67 59 34.61 2 1 0.616 0.615 0.727 0.701 0.454 0.468
26 SHANAVAS 45 F CASE 8 8.4 9 4.3 4.6 4.2 2.4 2.9 2.4 74.8 46.6 67.7 157 104 84 12.98 1 1 0.855 0.863 0.951 0.983 0.551 0.608
27 DHANALAKSHMI 47 F CASE 8 6.9 9 3.24 5.3 4.8 2.4 3 2.7 26.2 13.3 33 154 113 82 27.83 3 3 0.904 0.946 1.001 1.038 0.652 0.704
28 MATHIAZHAGI 22 F CASE 10.5 7.6 9.6 5 4.1 4.2 2.3 2.3 2.4 2 47.1 48 331 194 101 45.46 2 1 0.97 1.062 1.088 1.172 0.618 0.643
29 DEVAKURUBAI 27 F CASE 9.9 6.9 8.6 4.9 3.6 3.8 2.2 2.3 2.2 17 6 33 235 206 102 17.32 3 3 0.718 0.809 0.966 1.124 0.513 0.598
30 VELU 32 M CASE 9.1 7 9.1 3.6 4.6 3.4 2.3 2.2 2.3 68.7 30.6 84.9 109 94 78 24.35 3 2 0.873 0.924 1.163 1.194 0.663 0.726
31 RAVI II 44 M CASE 8 8.4 8.6 3.5 3.8 3.6 2.3 2.4 2.2 84.7 50.9 68.7 215 155 176 34.09 1 1 0.595 0.628 0.776 0.854 0.524 0.576
32 SHERIFF 40 M CASE 9 7.2 6.8 4.8 4 2.9 2.3 2.3 2.2 51.1 17.3 87.7 185 96 278 24.07 2 1 0.637 0.688 0.883 0.9 0.489 0.553
33 RAJA 30 M CASE 8.7 8.3 9.1 4.7 4.9 3.4 2.3 2.2 2.3 14 57.5 73.7 226 151 151 48.8 2 2 0.82 0.889 0.909 0.957 0.592 0.623
34 SIVAKUMAR 27 M CASE 9.5 6.4 9.2 4.2 4.7 4.1 2.7 2.3 2.2 55 12.8 62 260 207 106 20.9 2 1 0.722 0.834 0.944 1.132 0.59 0.622
35 BALASUBRAMANIAM 40 M CASE 10 8.2 9.4 3.7 4.2 3.9 0.81 2.3 1.9 32.5 71.2 97 117 78 116 15 2 2 0.664 0.71 1.042 1.207 0.664 0.618
36 singaravelu 40 M CASE 8.9 7.2 8.6 3.6 3.8 4 2.3 2.3 2.6 121.3 33.2 29.8 253 251 182 28.8 2 2 0.965 0.989 0.848 0.876 0.671 0.675
37 SIVAKUMAR3 31 M CASE 9 8.1 8.8 3.7 7.3 3.8 2.3 2.3 2.2 38.9 20.9 36.9 81 110 97 24.5 2 2 1.027 1.029 1.068 1.081 0.71 0.725
38 KANIAPPAN 29 M CASE 9.2 7.9 9.3 4 3.8 3.9 2.2 2.3 2.3 50.1 10 24.3 42 22 36 21.94 3 3 1.143 1.196 1.154 1.151 0.711 0.712
39 SARAVANAN 38 M CASE 8.5 8.1 10 3.5 3.4 3.8 2.2 1.7 2.1 184 20.8 24.3 342 97 88 27.55 2 1 0.539 0.582 0.69 0.772 0.515 0.529
40 SHANMUGAM 43 M CASE 9.1 6.1 8.6 3.7 3.2 3.4 2.3 1.3 2.2 83.2 8.7 18.4 212 193 102 17.07 3 3 0.682 0.713 0.72 0.811 0.522 0.534
SL.
NO NAME AGE SEX GROUP P Ca PO Ca F Ca P Ph PO Ph F Ph P Mg PO Mg F Mg P PTH PO PTH F PTH P SAP PO SAP F SAP P VITD Tross iv cal
PREOP 
BMD 
FEMOR
POSTOP 
BMD 
FEMUR
PREOP 
BMD 
LUMBAR
POSTOP 
BMD 
LUMBAR
PREOP BMD 
FOREARM
POSTOP BMD 
FOREARM
1 MANJULA 35 F CONTROL 9.8 8.6 8.8 4 3.9 4.5 3.1 1.4 1.9 36.2 0.01 40.1 51 42 46 18.03 2 1 0.995 0.997 1.223 1.234 0.915 0.901
2 JANSI 34 F CONTROL 9.6 8.6 8 4.1 4.46 4 3.3 1.8 2.3 48.1 7.4 33.3 88 79 76 12.08 2 2 0.897 0.901 1.014 1.012 0.74 0.758
3 PUSHPALATHA 27 F CONTROL 9.2 8.2 8.5 4.5 5.4 4.2 1.2 1 2.5 65.6 0.01 65.1 64 57 41 9.2 2 1 1.09 1.11 1.291 1.289 0.89 0.899
4 SELVI 26 F CONTROL 9.4 9.3 9.1 3.9 3.4 3.4 2.7 0.9 2.4 60.7 32.3 39.4 51 51 59 11.46 1 1 1.045 1.043 1.271 1.269 0.655 0.674
5 ANISHA 25 F CONTROL 8.8 8.2 8.7 2.4 2.9 1.7 1.58 2.01 2.4 55.8 17.6 55.2 75 63 67 15.66 2 1 1.096 1.098 1.112 1.114 0.843 0.832
6 SELVI VENDA 40 F CONTROL 8.3 7.6 9.1 3.2 3.8 3.4 1.7 1.83 2.1 23 18.8 48 65 63 71 16.89 2 1 1.082 1.84 1.238 1.2236 0.739 0.734
7 SRIDHAR 37 M CONTROL 8.3 8.5 9.3 2.4 3.2 3.8 1.56 1.4 1.31 49.9 14.9 42.3 78 77 77 14.2 2 1 0.947 0.976 1.11 1.053 0.737 0.744
8 SRINIVASAN 34 M CONTROL 10.6 7.6 5.3 4.6 2.2 2.6 77.9 13.5 81 57 20.3 3 1 0.959 0.923 1.098 1.046 0.711 0.734
9 POONGAVANAM 38 F CONTROL 9.6 8.6 9.1 3.3 4.3 3.8 1.73 1 2.1 36.8 17.8 44 31 34 56 8.61 1 1 0.985 0.984 1.212 1.232 0.838 0.832
10 THILAGAVATHY 30 F CONTROL 9.6 9.2 6.1 2.1 3.9 5.3 1.85 2.1 1.31 28.5 22 19.9 59 56 61 13.85 1 1 0.872 0.873 0.995 1.004 0.671 0.662
11 AMULRANI 25 F CONTROL 9.2 9 8 5 6.2 5.2 2 1.37 2 66.9 0.1 7 113 78 74 24.6 2 2 0.966 0.972 1.095 1.1 0.837 0.845
12 SELVARAJ 52 M CONTROL 10.6 10 9.4 3.1 4.1 4 1.8 2 2.5 26 19.8 59 74 94 40 38 1 1 0.983 0.994 1.146 1.148 0.75 0.746
13 KARPAGAM 26 F CONTROL 10.4 8.2 9.2 4.4 4.4 4.5 1.6 2.1 2.4 48.6 11.9 56 98 71 79 45 2 1 0.79 0.794 0.928 0.932 0.581 0.605
14 SHANTHI P 45 F CONTROL 9.1 8.8 9.5 3.6 4.3 4.4 2.4 2.1 2.6 24 5.5 15.6 56 40 43 19.4 1 1 1.082 1.083 1.113 1.109 0.798 0.796
15 NINEYAPAN 45 M CONTROL 9.9 10.3 9.6 4.3 4.7 4.2 2.3 2 2.2 2 1 22 72 69 76 52.2 2 1 0.949 0.952 1.028 1.42 0.999 0.976
16 AMBIKA 23 F CONTROL 9.9 9.4 9.2 4.8 5.2 4.4 1.82 1.9 2.4 57.1 30.1 27.8 41 41 67 19.2 1 1 0.991 0.996 1.03 1.04 0.784 0.792
17 DILSHAD 28 F CONTROL 9.3 8.3 8.9 3.7 4.3 3.1 1.71 2.01 2.7 46 9.9 37.5 49 46 46 44.5 2 2 0.958 0.956 1.027 1.033 0.652 0.655
18 DURAISAMY 46 M CONTROL 9.5 9.4 3.7 3.5 2.2 1.32 39.1 25.3 58 57 55.48 1 1 0.799 0.799 0.915 0.922 0.647 0.685
19 JAIBUNBEE 40 F CONTROL 9.7 9.4 9.3 4.8 3.9 4.1 2.4 2.4 2.4 40.3 20.8 33.4 91 80 76 33.7 1 1 1.031 1.033 1.089 1.088 0.735 0.744
20 SUGUNA D 41 F CONTROL 9.7 9 9.2 4.9 4 3.8 2.5 2.3 2.2 49.3 44.5 48 58 48 56 22.47 1 1 1.046 1.048 1.161 1.152 0.858 0.854
21 DIVYA 23 F CONTROL 9 8 8.4 4.5 5.4 4.6 2.5 2.5 2.4 58.9 21.3 67.2 68 96 60 14.86 2 2 0.897 0.901 1.092 1.118 0.554 0.609
22 MOORTHI 38 M CONTROL 10 11 9.1 3.74 3.8 4.5 2.5 2.4 2.6 28.6 17.6 38.5 120 112 80 17.28 1 1 1.083 1.084 1.051 1.062 0.795 0.803
23 LAKSHMI 23 F CONTROL 10 9 9.4 4.2 4 3.8 2.4 2.4 2.2 48.4 35.8 44 42 35 56 23.5 1 1 0.949 0.953 1.133 1.121 0.574 0.579
24 ADHILAKSHMI 30 F CONTROL 9 8.7 9.2 3.7 3.9 3.6 2.3 2.2 2.6 45 23 46 57 76 56 17.39 1 1 1.011 1.017 1.125 1.115 0.739 0.741
25 POONGODI 43 F CONTROL 9 9 8.6 3.8 4.9 3.6 2.2 2.2 2.3 53.1 30 71.4 68 60 57 16.89 1 1 1.135 1.136 1.398 1.389 0.807 0.812
26 JAMMUNA 44 F CONTROL 10 9.1 9.3 4.6 5.4 2.5 2.3 2.3 2.2 30.3 14.3 29.9 107 89 95 27.42 1 1 1.054 1.064 1.206 1.199 0.677 0.678
27 CHARULATHA 27 F CONTROL 11 10.2 3.9 3.6 2.3 2.2 61.2 54 125 105 28.37 1 1 1.076 1.084 1.164 1.169 0.691 0.678
28 DHANAM 30 F CONTROL 7.9 9.9 9.1 5.5 4.6 4.3 2.5 2.3 2.3 25.9 12 30.2 61 54 67 50.95 1 1 1.029 1.033 1.165 1.168 0.722 0.712
29 DEEPA 18 F CONTROL 9.2 9 8.8 5.3 4.6 4.3 2.5 2.1 2.4 15.6 10 19.6 81 56 77 31.02 2 2 0.949 0.967 1.049 1.053 0.615 0.654
30 RAJENDRAN 50 M CONTROL 8 9 8.7 3.5 3.5 3.8 2.2 2.3 2.2 35.4 30.9 66.5 84 63 84 61.68 1 1 1.104 1.099 1.141 1.143 0.799 0.789
31 THULUKANAM 28 M CONTROL 9.5 8.7 8.6 3.7 3 3.4 2.2 2.2 2.6 36.4 23.3 33.5 65 87 74 25.6 2 1 1.528 1.53 1.407 1.411 0.929 0.927
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